Buy Aceto Before Earnings - $ACET

$ACET is a BUY.

This producer of chemicals used in generic drugs is a recent addition to our IXTHYS Letter Portfolio. The company produces $545M in revenues and shares trade at a low 22x earnings, and 9x forward estimates. Net income has increased an average of 27% per year over the past 5 years. A 0.8x sales metric shows upside potential.

Zacks Research gives ACET a top rank of 1 (strong buy) for its recent upward revisions in earnings estimates.

Shares pay 1.6% dividend, and 10% of the float is short. We may see a squeeze in play when the company reports earnings on Thursday.

The chart shows a bullish base breakout in progress.

Posted to Dr. Stoxx Options Letter on May 02, 2017 — 12:05 PM
Comments ({[comments.length]})
Sort By:
Loading Comments
No comments. Break the ice and be the first!
Error loading comments Click here to retry
No comments found matching this filter
Want to add a comment? Take me to the new comment box!